<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836068</url>
  </required_header>
  <id_info>
    <org_study_id>J1331</org_study_id>
    <secondary_id>NA_00083734</secondary_id>
    <secondary_id>1P30AI094189-01A1</secondary_id>
    <nct_id>NCT01836068</nct_id>
  </id_info>
  <brief_title>Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals</brief_title>
  <official_title>Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1-infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find out if it is possible for HIV-1 patients to maintain antiretroviral medications
      during allogeneic bone marrow transplant
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine the feasibility of maintaining optimal ART in HIV-1 infected patients during
      allogeneic hematopoietic stem cell transplant (HSCT). The primary outcome is the fraction of
      patients who maintain any form of anti-retroviral therapy, including enfuvirtide monotherapy,
      through day 60 post-transplant. If patients are unable to take oral anti-retroviral
      medications, but are able to tolerate subcutaneous enfuvirtide monotherapy this will be
      considered maintenance of ART. Failure to maintain ART will be defined as ≥ 24 hours without
      any anti-retroviral therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the feasibility of maintaining optimal ART in HIV-1 infected patients during allogeneic HSCT</measure>
    <time_frame>24 hours</time_frame>
    <description>Failure to maintain anti retroviral therapy for 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of copies of HIV-1 DNA in blood mononuclear cells at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure the number of copies of HIV-1 DNA per million peripheral blood mononuclear cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of copies of HIV-1 DNA in blood mononuclear cells at 12 weeks</measure>
    <time_frame>12 weeks post-intervention</time_frame>
    <description>Measure the number of copies of HIV-1 DNA per million peripheral blood mononuclear cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of copies of HIV-1 DNA in blood mononuclear cells at 24 weeks</measure>
    <time_frame>24 weeks post-intervention</time_frame>
    <description>Measure the number of copies of HIV-1 DNA per million peripheral blood mononuclear cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of copies of HIV-1 DNA in blood mononuclear cells at 36 weeks</measure>
    <time_frame>36 weeks post-intervention</time_frame>
    <description>Measure the number of copies of HIV-1 DNA per million peripheral blood mononuclear cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of copies of HIV-1 DNA in blood mononuclear cells at 52 weeks</measure>
    <time_frame>52 weeks post-intervention</time_frame>
    <description>Measure the number of copies of HIV-1 DNA per million peripheral blood mononuclear cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of copies of HIV-1 DNA in blood mononuclear cells at 2 years</measure>
    <time_frame>2 years post-intervention</time_frame>
    <description>Measure the number of copies of HIV-1 DNA per million peripheral blood mononuclear cells.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The incidence of acute graft-vs-host disease</measure>
    <time_frame>2 years post-intervention</time_frame>
    <description>Describe the incidence of acute graft-vs-host disease via the Keystone criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>The severity of acute graft-vs-host disease</measure>
    <time_frame>2 years post-intervention</time_frame>
    <description>Describe the severity of acute graft-vs-host disease via the Keystone criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of chronic graft-vs-host disease as defined by the NIH consensus criteria</measure>
    <time_frame>2 years post-intervention</time_frame>
    <description>Describe the incidence chronic graft-vs-host disease via the NIH consensus criteria.</description>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of chronic graft-vs-host disease as defined by the Seattle criteria</measure>
    <time_frame>2 years post-intervention</time_frame>
    <description>Describe the incidence chronic graft-vs-host disease via the Seattle criteria.</description>
  </other_outcome>
  <other_outcome>
    <measure>The severity of chronic graft-vs-host disease as defined by the NIH consensus criteria</measure>
    <time_frame>2 years post-intervention</time_frame>
    <description>Describe the severity of chronic graft-vs-host disease via the NIH consensus criteria and the Seattle criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>The severity of chronic graft-vs-host disease as defined by the Seattle criteria</measure>
    <time_frame>2 years post-intervention</time_frame>
    <description>Describe the severity of chronic graft-vs-host disease via the Seattle criteria</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Enfuvirtide monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enfuvirtide 90 mg subcutaneously every 12 hours will be also be administered during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions with conditioning regimens in patients who require ritonavir-boosted PI containing ART regimens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enfuvirtide</intervention_name>
    <description>Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions</description>
    <arm_group_label>Enfuvirtide monotherapy</arm_group_label>
    <other_name>Fuzeon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection, as documented by a rapid HIV-1 test or any FDA-approved HIV-1 enzyme
             or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at any
             time prior to study entry. Alternatively, two HIV-1 RNA values &gt; 200 copies/mL at
             least 24 hours apart performed by any laboratory that has CLIA certification, or its
             equivalent may be used to document infection.

          -  Patients must be ≥ 18 years of age.

          -  Plan to undergo a Myeloablative, HLA matched or partially HLA-mismatched
             (haploidentical), related-donor bone marrow transplantation that includes high-dose
             posttransplantation Cy using bone marrow from a related donor:

          -  Plan to undergo a Nonmyeloablative, HLA matched or partially HLA-mismatched,
             related-donor bone marrow transplantation that includes high-dose posttransplantation
             Cy using bone marrow from a related donor:

        Exclusion Criteria:

          -  Patients with a known history of enfuvirtide resistance will not be eligible for this
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Ambinder, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>April 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV positive</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Bone Marrow Transplant</keyword>
  <keyword>Allogeneic BMT</keyword>
  <keyword>BMT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enfuvirtide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

